This study aimed to find out if androgen deprivation therapy (ADT) is more effective used with docetaxel (Taxotere) or abiraterone (Zytiga). There was no significant difference found between the two treatment options. 

This article presents the results of a phase III clinical trial that evaluated the safety and efficacy of Toremifene (Acapodene) for lowering fracture risk in men with prostate cancer receiving androgen deprivation therapy (ADT). The risk of spinal fractures was significantly reduced in patients who received Toremifene.

This study aimed to evaluate post-traumatic stress disorder (PTSD) in patients who have had treatment for cancer. This study found that a number of patients undergoing cancer treatment developed PTSD after treatment and recommended that supports are put in place. 

This article outlines current guidelines regarding nutrition and physical activity for cancer survivors.
 

This study aimed to evaluate the usefulness of transurethral resection of the prostate (TURP). This study found that TURP is a surgical option to relieve bladder obstruction in patients with locally advanced prostate cancer.

The aim of this study is to determine the effectiveness and safety of ipatasertib (GDC-0068) in combination with abiraterone (Zytiga) and prednisone/prednisolone (Deltasone) in men with metastatic castration-resistant prostate cancer. The main outcome to be measured is time to disease progression.

Prostate cancer is cancer that starts in the prostate gland (figure 1). The prostate gland is a small, walnut-sized structure that makes up part of a man's reproductive system by producing fluid that is part of semen. It sits below the bladder and in front of the rectum, and forms a ring around the urethra, the tube that carries urine out of the body.

Prostate cancer occurs most often in men older than 50. Although prostate cancer is very common, most men do not die from it. This is because prostate cancer usually grows very slowly.